OncoMatch/Clinical Trials/NCT05504265

Perioperative Analgesia Modes in Minimally Invasive Esophagectomy

Is NCT05504265 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2/3 trial studies multiple treatments including Preemptive flurbiprofen axetil and Postoperative flurbiprofen axetil for esophageal cancer.

Phase 2/3RecruitingCancer Institute and Hospital, Chinese Academy of Medical SciencesNCT05504265Data as of Jun 2026Location: China

Treatment: Preemptive flurbiprofen axetil · Postoperative flurbiprofen axetil — This study was designed to compare analgesic efficacy and safety of different perioperative analgesic modes in minimally invasive esophagectomy for esophageal cancer.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

Preemptive flurbiprofen axetilPostoperative flurbiprofen axetil

Cancer type

Esophageal Carcinoma

Demographics

Ages ≤ 75

Lab requirements

Cardiac function

Preoperative cardiac function grade ≥ III or coronary artery stenosis [excluded]

Preoperative cardiac function grade ≥ III or coronary artery stenosis

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT05504265 currently recruiting?

Yes, this trial is currently recruiting patients.

Is there an age limit?

Yes. Patients must be 75 years or younger.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify

Esophageal Carcinoma trials